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The neuropathological features associated with Alzheimer’s disease (AD) include the presence of extracellular amyloid-𝛽 peptide-
containing plaques and intracellular tau positive neurofibrillary tangles and the loss of synapses and neurons in defined regions of
the brain. Dipeptidyl peptidase 10 (DPP10) is a protein that facilitates Kv4 channel surface expression and neuronal excitability.This
study aims to explore DPP10
789
protein distribution in human brains and its contribution to the neurofibrillary pathology of AD
and other tauopathies. Immunohistochemical analysis revealed predominant neuronal staining of DPP10
789
in control brains, and
the CA1 region of the hippocampus contained strong reactivity in the distal dendrites of the pyramidal cells. In AD brains, robust
DPP10
789
reactivity was detected in neurofibrillary tangles and plaque-associated dystrophic neurites, most of which colocalized
with the doubly phosphorylated Ser-202/Thr-205 tau epitope. DPP10
789
positive neurofibrillary tangles and plaque-associated
dystrophic neurites also appeared in other neurodegenerative diseases such as frontotemporal lobar degeneration, diffuse Lewy
body disease, and progressive supranuclear palsy. Occasional DPP10
789
positive neurofibrillary tangles and neurites were seen in
some aged control brains.Western blot analysis showed both full length and truncated DPP10
789
fragments with the later increasing
significantly in AD brains compared to control brains. Our results suggest that DPP10
789
is involved in the pathology of AD and
other neurodegenerative diseases.
1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterized pathologically by the presence of
extracellular amyloid plaques containing the amyloid-𝛽
peptide (A𝛽) and intracellular neurofibrillary tangles (NFTs)
containing hyperphosphorylated microtubule-associated
protein tau and loss of synapses and neurons in select brain
regions [1–3].The aetiology of AD is complex, with amajority
of cases being sporadic and approximately 10% being inher-
ited. Mutations have been identified in genes encoding
amyloid precursor protein (APP) [4, 5], presenilin 1 (PS1), and
PS2 in a small subset of familial AD cases. In sporadic AD
cases, polymorphisms of apolipoprotein E4 and other genes
have been associated with an increased risk of developing
the disease [6].
Oxidative stress, impaired energy metabolism, and dis-
ruption of neuronal Ca2+ regulation have all been impli-
cated in the cellular pathophysiology. Although experimental
approaches indicate that A𝛽 deposition plays an important
role in the neurodegenerative process in AD [7, 8], the mech-
anism underlying the relentless progression of neurofibrillary
pathology and neuronal death remains to be fully elucidated.
Over the last decade there have been a number of studies
demonstrating that potassium channel dysfunction may be
involved in the pathogenesis of AD [9–13].
Neuronal excitability is finely controlled by variousmem-
branous channels and associated proteins. In the central
nervous system, the rapidly inactivating voltage-gated potas-
sium channels (Kv channels) are the major determinants
of dendritic excitability [14]. In particular, Kv4 channels, a
subfamily of Kv channels, account for a large portion of the
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Table 1: Primary antibodies used in this study.
Antibody/antiserum Species Epitope Source Dilution
DPP10789 (polyclonal) Rabbit DPP10789 𝑁-terminal intracellular domain This lab 1 : 100
Anti-GFP (polyclonal) Rabbit GFP Invitrogen, USA 1 : 3000
AT8 Mouse Specific for tau phosphorylation at Ser 202 and/or Thr205
Innogenetics,
Belgium 1 : 1000
Tau2 Mouse Phosphorylated and nonphosphorylated tau Novocastra,UK 1 : 1000
A4 Mouse 𝛽-Amyloid
Professor Colin
Masters,
Melbourne
University
1 : 250
Anti-𝛽III-tubulin monoclonal Ab Mouse 𝐶-Terminus of 𝛽III-tubulin Promega, USA 1 : 10000
somatodendritic inactivating current in neurons in regulat-
ing firing frequency and signal processing in dendrites. The
Kv4 channels are composed of the pore-forming subunits,
various auxiliary subunits, and other interacting proteins
such as Kv channel interacting proteins and dipeptidyl
peptidase-like proteins DPP6 and DPP10 [15–17].
Indeed, potassium channel dysfunction has been demon-
strated in fibroblasts and platelets of AD patients [9, 10]. Post-
mortem studies have also showed alterations of potassium
channel expression in AD brains [18]. Several publications
have demonstrated thatA𝛽 is involved inKv channel function
and may even play a physiological role in controlling neu-
ronal excitability [19, 20]. In addition, Kv channel interacting
protein 3, also known as calsenilin, is a presenilin binding
protein [21] that preferentially interacts with the familial AD
associated 𝐶-terminal fragment of PS2 [22]. Moreover, the
application of A𝛽 peptide to cultured cells increases both Kv
channel interacting protein 3mRNA and protein expression
as well as cell death. The A𝛽 toxicity can be prevented by
blocking expression of Kv channel interacting protein 3 [23].
Furthermore, in a study using a transgenic model of Alz-
heimer’s disease, some potassium channels in hippocampal
neurons were found to be absent [24]. Liu et al. reported that
a potassium channel activator diazoxide ameliorated A𝛽 and
tau pathologies and improvesmemory in the 3xTgADmouse
model [25]. Thus there is a body of research that suggests
that potassium channels or their associated proteins might be
involved in steps leading to the neurodegeneration observed
in AD.
DPP10 belongs to the dipeptidyl peptidase 4 (DPP4)
gene family sharing 59% amino acid sequence similarity with
DPP4, an atypical serine protease [26, 27]. However DPP10 is
missing the nucleophilic Ser residue in the catalyticmotif and
lacks enzyme activity. So far, four splice variants have been
reported for DPP10. As a result of alternate splicing of the
first exon, each variant has a short divergent cytoplasmic𝑁-
terminus. The remaining protein of each variant is identical
and consists of a highly conserved juxtamembrane, trans-
membrane, and large extracellular 𝐶-terminal domain. Kv4
channels containing different DPP10 variants display distinct
inactivation kinetics and voltage dependence at depolarized
potentials, indicating that the cytoplasmic portion of the
DPP10 protein influences the inactivation properties [28].We
have previously cloned the short form of DPP10 (DPP10
789
)
from human brain [27]. To further characterise its function,
we generated an antibody specific to DPP10
789
to examine
the expression of DPP10
789
in human brains. Here we report
that DPP10
789
is predominantly localized to neuronal soma
and dendrites in the neocortex and subcortical grey matter
in control brains and abnormally accumulated in Alzheimer’s
disease and other diseases characterised by tau positive
pathologies.
2. Materials and Methods
2.1. PrimaryAntibodies. The peptide H-MRKVESRGEGGRE-
OH containing the 𝑁-terminus of DPP10
789
was ordered
from MIMOTOPES (VIC, Australia). This 𝑁-terminal
sequence shares no sequence identity with the two other
forms of DPP10 or the𝑁-termini of the four DPP6 isoforms
and therefore will only detect the DPP10
789
isoform of DPP10
[29]. Rabbits were immunised by the peptide mixed with
Freund’s complete adjuvant.DPP10
789
antiserumwas purified
using an affinity column prepared from the respective immu-
nising peptide (ABGENT, Inc., San Diego, CA, USA) conju-
gated to 6% cross-linked beaded agarose. A sequence homo-
logy search was performed using BlastP into the GenBank
database and the peptide sequence only had significant
homology with DPP10
789
. All other primary antibodies, their
source, and the dilution used in the present studies are listed
in Table 1.
2.2. Human Cases. Samples from the hippocampus, the
frontal and temporal cerebral cortex, the entorhinal and
cingulated cortex, and the cerebellum were obtained from
individuals listed in Table 2. Brain tissue was collected by
the National Health Medical Research Council (NHMRC)
Brain Bank of South Australia following NHMRC ethical
guidelines. All diseased cases had a clinical diagnosis while
control cases showed no clinical signs of dementia.
2.3. Cell Culture and Sample Preparation. The human kidney
epithelial cell line 293T was cultured as described previously
[30]. Transfection with GFP-DPP10
789
construct was carried
out by methods previously described using Fugene 6 (Roche,
USA) [27, 30]. After 48 hrs, cell extracts were resuspended in
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Table 2: Human cases analysed in this study.
Brain Bank
number Gender Age
Postmortem
delay (h)
Neuropathological
diagnosis
SA0123 M 80 21 AD
SA0126 F 79 31 AD
SA0134 F 69 23 AD
SA0143 M 84 15 AD
SA0148 M 81 14 AD
SA0129 F 88 9 Early AD
SA0087 M 71 15.5 FTLD
SA0069 M 69 31 DLBD
SA0079 F 82 31 DLBD
SA0063 F 81 7 DLBD
SA0094 M 74 24 DLBD
SA0035 F 72 28 PSP
SA0043 F 69 10 PSP
SA0106 M 66 29 PSP
SA0136 F 80 20 PSP
SA0010 M 58 14 Control
SA0013 M 64 23 Control
SA0021 F 72 7 Control
SA0030 M 69 48 Control
SA0031 F 61 8 Control
AD: Alzheimer’s disease, DLBD: diffuse Lewy’s body disease, FTLD:
frontotemporal lobar degeneration, PSP: progressive supranuclear palsy,
F: female, and M: male.
sonication buffer (20mM Tris pH 7.5, 5mM EGTA, 2mM
EDTA and 0.25M sucrose) and sonicated for 3 × 10 sec.
Following sonication cellular debris was removed by a brief
10,000 g centrifugation and then the supernatant underwent
a 30min 100,000 g centrifugation at 4∘C to pellet membrane
proteins. The membrane pellet was solubilized in sonication
buffer containing 0.5% Triton X-100, mixed with 4x sample
buffer (6% SDS, 40% sucrose, 150mM Tris pH 6.8, and
0.03% Bromophenol Blue), and incubated at 37∘C for 10mins
and run on 10% SDS-PAGE. The recombinant GFP-tagged
DPP10
789
protein was detected using either an anti-GFP
antibody (Cell Signaling Technology, USA) or the affinity
purified anti-DPP10
789
antibody described above.
2.4. Tissue Preparation. Brain tissues were fixed routinely by
immersion in a mixture of 4% paraformaldehyde and picric
acid. Series of each frozen section (450𝜇m thick) were cut
on a chilledmicrotome. Paraffin sections were cut (5–20 𝜇m),
mounted on gelatine coated glass slides, and dried in an oven
at 37∘C overnight.
2.5. Immunohistochemistry. Agreen fluorescent proteinGFP-
DPP10
789
construct with GFP fused to the 𝑁-terminus of
DPP10
789
was transiently transfected into 293T cells cultured
on a chamber slide as described previously [27]. After 48 h,
cells were washed with PBS and then fixed with 2% parafor-
maldehyde made in PBS. The affinity purified anti-DPP10
789
Ab was used to detect recombinant DPP10
789
protein. Mouse
anti-rabbit Alexa 596 (Molecular Probes, Eugene, OR) was
used as the secondary antibody for immunofluorescence
studies.
Free-floating sections of human brain (50 𝜇m)were incu-
bated with primary antibody for 48 h at 4∘C. Incubation with
the secondary biotinylated anti-rabbit or anti-mouse IgG was
performed for 1 hr at room temperature. Immunoreactions
were visualised with the avidin-biotin-peroxidase complex
(VECTASTAIN ABC system, Vector Labs, UK) and 3-3-
diaminobenzidine-4 HCl/H
2
O
2
(DAB, D5637 Sigma, USA).
Paraffin-embedded sections were treated similarly after
dewaxing, except that they were heat-treated (105∘C for
10min 1mM EDTA, pH 8.0 at 25∘C) before immunostaining.
Double-labelled immunohistochemistry was performed
on sections from AD cases. Selected free-floating sections
were incubated with both anti-DPP10
789
and AT8 antibody
(anti-phosphorylated tau protein), Tau2 antibody (detects
both phosphorylated and nonphosphorylated tau), or A4
antibody (anti-amyloid-𝛽). Anti-DPP10
789
antibodywas then
visualized by anti-rabbit IgG conjugated with Cy2 (Jackson
ImmunoResearch Laboratories Inc., USA) while anti-tau
antibody or anti-amyloid antibody was detected by anti-
mouse IgG conjugated with Cy3 (Jackson ImmunoResearch
Laboratories).
Whenever the A4 antibody was used, antigen retrieval
was performed before the blocking step by incubating the
sections in preheated sodium citrate buffer (10mM, pH 8.5)
at 80∘C for 30min.
2.6. Quantification of Lesions. Adjacent free-floating sec-
tions of hippocampus or cortex were immunostained with
DPP10
789
, AT8, or A4 antibody separately using the DAB
reaction as described above.The number of lesions was quan-
tified at 200 times of magnification under an Olympus BH-
2 light microscope (Tokyo, Japan) coupled to a MicroPub-
lisher 3.3 RTV digital camera (QIMAGING, Canada). In the
hippocampus, three fields (0.01mm2/field) from each region
of Ammon’s horn (CA1-4) were counted. In neocortical
sections, three fields per case were counted in each of layers
III to V. After each field was captured, the stage was moved
manually to a new field using fiducial landmarks to ensure a
completely nonredundant evaluation.
2.7. Tissue Homogenates. Hippocampuses of five AD cases
and four control caseswere dissected from fresh-frozen brain.
Samples were homogenized in 10 volumes of ice-cold sucrose
buffer (0.32M sucrose, 1mM EDTA, 5mMTris-HCl, and pH
7.4) containing 0.2% Triton X-100 and a protease inhibitor
cocktail (Sigma, USA). The homogenate was centrifuged at
10,000×g for 20min.The supernatant was saved and the pel-
let was then resuspended in ice-cold sucrose buffer and
homogenized again. The homogenate was solubilised for 1 hr
at 4∘C. Insoluble material was removed by centrifugation at
10,000×g for 30 min. The second supernatant was com-
bined with the first as hippocampal solubilised fraction.
After the estimation of protein concentration, aliquots of
homogenates were immediately subjected to incubation with
4 × SDS-PAGE sample buffer (250mM Tris-HCl, 8% SDS,
40% glycerol, 0.4M DTT, 0.04% Bromophenol Blue, and pH
6.8) at 37∘C for 20min. Protein (50 𝜇g) from each sample was
loaded and run on a 10% SDS-PAGE gel.
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Figure 1: Anti-DPP10
789
antibody characterization.TheGFP-DPP10
789
construct was transiently transfected into 293T cells. DPP10
789
protein
was stained with anti-DPP10
789
antibody followed by Cy3 goat anti-rabbit IgG (a).The green GFP fluorescence (b) and the overlay of the Cy3
and the GFP images (c). Scale bar is 20 𝜇m. Membrane fractions were prepared and run on a 10% SDS-PAGE gel. The transferred membrane
was immunoblotted with DPP10
789
antibody.TheDPP10
789
antibody recognized a 120 kDa band corresponding to the full-length GFP-tagged
DPP10
789
((d) far left lane). This 120 kDa band can be totally blocked with addition of the antigenic peptide for DPP10
789
antibody in the
blocking solution ((d) middle lane).The anti-GFP antibody detected the same band after the membrane was stripped and reprobed ((d) right
lane).
2.8. Immunoblot. Immunoblots were performed as described
previously [27] and incubated with the affinity purified
DPP10
789
antibody (final concentration at 1.25 𝜇g/mL) or
anti-𝛽III-tubulin monoclonal antibody (final concentration
0.1 𝜇g/mL) at 4∘C overnight. Bound antibodies were detected
using the SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce, IL, USA). The membrane was exposed to X-
OMAT diagnostic film (Kodak Scientific Light Systems, NY,
USA) and developed on a Kodak X-OMAT 1000 Processor
(Kodak Australasia, Pty. Ltd.).
2.9. Analytical Methods. The protein concentrations of brain
homogenates were measured using the Bradford assay (Bio-
Rad, USA) according to the manufacturer’s instructions.
Levels of DPP10
789
in brain homogenates were estimated by
immunoblot using the Quantity One (BioRad, USA) image
analysis software package and were adjusted by the level of
neuron specific protein 𝛽-tubulin. An independent 𝑡-test was
performed to compare the expression of DPP10
789
between
control and AD brains.
3. Results
3.1. Specificity of the DPP10
789
Antibody. To confirm the
specificity of the anti-DPP10
789
antibody, we used immun-
ofluorescence and immunoblots to examine the 293T cells
transfected with the GFP-DPP10
789
construct (Figures 1(a)–
1(d)). With immunofluorescence, all cells that expressed GFP
fluorescence were detected by the anti-DPP10
789
antibody
(Figures 1(a), 1(b), and 1(c)), indicating the antibody specifi-
cally bound to recombinant GFP-DPP10
789
chimeric protein.
Our DPP10
789
antibody was designed to detect the𝑁-termi-
nal sequence of DPP10
789
, while the anti-GFP antibody rec-
ognises the GFP protein. On immunoblot (Figure 1(d)), the
DPP10
789
antibody recognised a band around 120 kDa
(Figure 1(d), far left lane), corresponding to the expected
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molecularmass ofGFP-taggedDPP10
789
and being consistent
with our previous studies [27]. The 120 kDa band was also
detected by the anti-GFP antibody (Figure 1(d), right lane)
confirming that the band was the GFP-DPP10
789
chimeric
protein. Because 293T cells are derived from human kidney
epithelial cells that do not express the brain derivedDPP10
789
,
no endogenous DPP10
789
was detected by immunoblot. Thus
these results confirmed that the DPP10
789
antibody was
specific to DPP10
789
.
3.2. DPP10
789
in Control and AD Brains. To document the
cellular localisation of DPP10
789
protein in human brains,
we first immunostained free-floating brain sections from a
selection of control cases and cases with various neurodegen-
erative diseases (Table 2). In control brains, positiveDPP10
789
staining was predominantly associated with neurons in the
CA1 region of the hippocampus (Figures 2(a), 3(a), and 3(b)).
The pyramidal cells were particularly well stained, with
DPP10
789
reactivity extending well into the distal portion of
dendrites (Figures 3(a) and 3(b)).
In contrast, very strong punctate DPP10
789
immunoreac-
tivity was observed in AD brains especially in the hippocam-
pal regions. Close examination revealed that neurofibrillary
tangles and dystrophic neurites were robustly stained with
the DPP10
789
antibody. These positive structures were most
abundant in the hippocampal region, where staining was
most intense in the CA1 and subiculum areas (Figures 2(b)–
2(e) and 2(h)). This immunoreactivity was completely abol-
ished by the DPP10
789
antigenic peptide (Figure 2(i)), and
sections incubated with preimmunization serum omitting
the DPP10
789
antibody did not show any positive stain-
ing (data not shown), further indicating that the observed
immunostaining was specific.
At high magnifications, three types of DPP10
789
positive
neurofibrillary tangle-like structures were observed: (1) gran-
ular staining in the neuronal soma (Figure 2(j)), resembling
pretangle phosphotau aggregates; (2) condensed intraneu-
ronal staining (Figures 2(k), 2(l), and 2(o)), resembling intra-
neuronal tau NFTs; (3) less condensed extracellular staining
(Figures 2(m), 2(n), and 5(h)), resembling extraneuronal tau
NFTs and ghost tangles. In addition, DPP10
789
immunore-
activity was also detected significantly in dystrophic neurites
surrounding amyloid plaques (Figures 2(d), 2(e), arrows, and
2(p)) and in neuropil threads (Figure 2(q)).
The DPP10
789
positive tangles and dystrophic neurites
were also observed in the frontal, temporal, entorhinal, and
cingulate regions as summarized in Table 3. No DPP10
789
positive staining was observed in the cerebellum.
Similar results were also observed in paraffin-embedded
sections. DPP10
789
immunostaining was detected on the cell
body and surface of dendrites of the hippocampal region
in a control case (Figures 3(a), arrows, and 3(b)). DPP10
789
positive staining was also observed in NFTs and plaque-
associated dystrophic neurites in AD brain (Figures 3(c)–
3(h)). Thus the above results suggested that the increased
DPP10
789
staining was primarily accumulated in neurofibril-
lary tangles and dystrophic neurites.
3.3. DPP10
789
in Other Tauopathies. Because neurofibril-
lary tangle and dystrophic neurite pathologies also occur
in neurodegenerative diseases other than AD, including
PSP and FTLD and DLBD, these later cases were further
examined. Some DPP10
789
positive tangles and plaques were
also detected in these cases (Figure 4). Table 3 summarizes
the presence of DPP10
789
positive tangles and dystrophic
neurites. In the fourDLBDcases examined,DPP10
789
positive
tangles and dystrophic neurites were also observed in tem-
poral, hippocampal, and entorhinal cortex regions (Figures
4(b) and 4(e)). A few positive DPP10
789
tangles and plaques
in the hippocampal and entorhinal regions were observed in
PSP cases (Figure 4(c)). Occasionally weak DPP10
789
positive
tangles and plaques were detected in some aged control
brains.
3.4. DPP10
789
Colocalizes with Tau Protein but Not with
Amyloid-𝛽 in AD Brain. Because tau protein is a major com-
ponent of neurofibrillary tangles and dystrophic neurites, we
examined if DPP10
789
protein expression is associated with
tau protein expression. We used the DPP10
789
antibody and
anti-tau antibody (AT8) specific for phospho-Ser202/Thr-
205 to localise DPP10
789
and phosphorylated tau (p-tau)
by double immunofluorescence staining in the brains of
AD. We observed robust colocalization of DPP10
789
with p-
tau in most tangles and dystrophic neurites (Figure 5). In
neurofibrillary tangles, DPP10
789
and p-tau were fully colo-
calized (Figures 5(b), 5(e), and 5(g)). In plaques, DPP10
789
and p-tau were found in the larger sized dystrophic neurites
(Figure 5(d)). DPP10
789
was also present in intracellular
vesicle-like structures (Figure 5(f)) where only weak p-tau
staining was present. In the entorhinal region of the temporal
cortex, some DPP10
789
positive tangle-like structures were
devoid of p-tau staining (Figure 5(h)), indicating that the
DPP10
789
antibody might be able to detect either early or
late tangle stages—ghost tangles which are not detected by
AT8. Double staining using the DPP10
789
antibody and Tau2
antibody (detects both phosphorylated and nonphosphory-
lated tau) also showed colocalization of DPP10
789
and tau in
neurofibrillary tangles and dystrophic neurites (Figures 5(a)
and 5(c)).
The other major pathological hallmark of AD is the
neuritic amyloid plaques located in the extracellular space
of the brain, comprised of an aggregated A𝛽 peptide core
surrounded by dystrophic neurites. As theDPP10
789
antibody
showed strong immunoreactivity in plaque-associated dys-
trophic neurites, it was also examined if DPP10
789
colocalized
with A𝛽 peptide. Double immunofluorescence revealed that
DPP10
789
positive dystrophic neurites were mostly present
in the A𝛽 core of senile plaques. While both DPP10
789
and
A𝛽 positive staining were observed within the same plaque
region, they were not colocalized; the red A𝛽 staining was
distributed as amyloid aggregation, with the green DPP10
789
positive dystrophic neuritesmingling randomly (Figure 5(i)).
The intrahippocampal distribution of DPP10
789
positive
neurofibrillary tangles (NFTs) followed the pattern estab-
lished for p-tau positive ones, with the greatest number of
involved neurons lying within the CA1 region of Ammon’s
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(d) (e) (f)
(g) (h) (i) (j)
(k) (l) (m) (n) (o) (p) (q)
Figure 2: Immunostaining of DPP10
789
in free-floating sections of control and AD brains. DPP10
789
immunostaining in the CA1 region of a
control brain (a), CA1 and subiculum region (b, c, and d), CA2 (e), inferior frontal cortex (f), cingulated cortex (g), inferior temporal cortex
(h), and inferior temporal cortex section blocked with antigenic peptide (i) in AD brains. DPP10
789
staining was found in granular structures
in the neuronal soma (j), NFT with extensions into dendrites of pyramidal neurons (k), globose NFT (l), extracellular ghost tangle (m), flame
shaped NFT (n), slender tangle of the subiculum with long extension into apical dendrite (o), plaque-associated dystrophic neurites (p), and
neuropil threads (q). Scale bar is 200𝜇m (b), 50 𝜇m (a, c–i), and 10 𝜇m (j–q). Arrows in (d) and (e) indicate staining in plaque-associated
dystrophic neurites in AD brain.
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(c) (d)
(e) (f) (g) (h)
Figure 3: Immunostaining ofDPP10
789
in paraffin sections from control andADbrains. DPP10
789
reactivity was observed in the frontal cortex
of a control individual (a, b), and arrows indicate the surface staining of DPP10
789
in dendrites. DPP10
789
positive staining was increased in
AD brain (c, d) and in NFTs (e–h). Scale bar is 50 𝜇m (a–d) and 10 𝜇m (e–h).
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(a) (b)
(c) (d) (e)
(f) (g) (h)
Figure 4: DPP10
789
immunostaining in free-floating brain sections of other tauopathies. DPP10
789
positive NFTs were observed in the
hippocampus of FTLD (a, d and g) and PSP (f) and superior frontal brains sections from patients with DLBD (b, e). DPP10
789
staining
in plaque-associated dystrophic neurites in DLBD and PSP brains (c and h, resp.). Scale bar is 50𝜇m (a, b, and f–h) and 10 𝜇m (c–e).
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(a) (b)
(c) (d)
(e)
(f) (g)
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(i)
Figure 5: DPP10
789
and tau colocalization in AD. Immunohistochemical colocalization of DPP10
789
with phosphorylated tau (p-tau) in
tangles and plaque-associated dystrophic neurites. DPP10
789
(green) partially or fully colocalized with p-tau (red) in tangles (a, b, e, and g)
and in plaque-associated dystrophic neurites (c, d). DPP10
789
was also present in intracellular vesicle-like structures (f) where very weak
staining for p-tau was present. DPP10
789
immunoreactivity was also found in some tangles in the entorhinal region which were devoid of
p-tau staining (h). DPP10
789
(green) did not colocalize with amyloid-𝛽 plaques (red) in AD brain (i). Scale bar is 10 𝜇m. (a) and (c) used Tau2
ab and the remaining images are with AT8 ab.
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Table 3: Summary of the DPP10789 positive staining in NFT and plaque-associated dystrophic neurites observed in control and neurodegen-
erative disease cases.
Case number Neuropathologicaldiagnosis
Frontal cortex Temporal cortex Hippocampus Entorhinal cortex Cingulate cortex
Tangle Plaque Tangle Plaque Tangle Plaque Tangle Plaque Tangle Plaque
1 SA0123 AD − +++ +++ +++ +++ +++ +++ +++ ++ +++
2 SA0126 AD +++ ++ +++ +++ ++ +++ +++ ++ ++ ++
3 SA0134 AD + +++ − +++ +++ ++ N/A N/A + +++
4 SA0143 AD + + +++ ++ +++ +++ +++ +++ + +
5 SA0148 AD +++ +++ − +++ +++ +++ +++ +++ +++ +++
6 SA0129 Early AD + + + + +++ ++ +++ + − −
7 SA0069 DLBD ++ ++ − +++ ++ ++ +++ +++ + ++
8 SA0079 DLBD − − − − − ++ − − − −
9 SA0094 DLBD − − +++ +++ + ++ ++ ++ + +
10 SA0063 DLBD − − + − + + − − − −
11 SA0087 FTLD − − − − +++ + ++ − − −
12 SA0035 PSP − − + − + − N/A N/A − −
13 SA0043 PSP + + + + ++ + ++ ++ + −
14 SA0106 PSP − − − − − − ++ N/A − −
15 SA0136 PSP − − − + − ++ +++ + − −
16 SA0010 Control + − − + − − − − − +
17 SA0013 Control − − − − + − − − − −
18 SA0021 Control − − − − + − + − − −
19 SA0030 Control − − + − − − N/A N/A + +
20 SA0031 Control − − − − N/A N/A N/A N/A − −
The number of lessons was counted at ×200 magnification under an Olympus BH-2 light microscope (Tokyo, Japan).
N/A: sample not available; −: negative; +: 1–5 lesions/field; ++: 5–10 lesions/field; +++: >10 lesions/field.
horn, followed by CA2, CA3, and CA4 (Figure 6(a)). In the
neocortical region, staining was detected mainly in layers
III–V. Approximately 67% of p-tau positive NTFs and 40%
A𝛽 positive neuritic plaques (NPs) contained anti-DPP10
789
immunoreactivity in these regions (Figure 6(b)).
3.5. Truncated DPP10
789
Is Elevated in AD Tissue. DPP10
789
protein levels were analyzed in the hippocampus as it is a
rich source of both NFTs and NPs.TheDPP10
789
Ab detected
three major mobilities: 100 kDa, 50 kDa, and 37 kDa (Figure
7(a)) in immunoblots. The 100 kDa band represents the
full-length DPP10
789
protein [27]. Samples from both AD
and control brains showed similar density of this band. The
50 kDa and 37 kDa bands observed are probably truncated
forms of DPP10
789
which are less than half the size of intact
DPP10
789
and have retained the𝑁-terminus, suggesting that
the DPP10
789
has been proteolytically processed. Noticeably,
ADbrain samples had higher density bands of these two trun-
cated forms compared to control samples. Quantitation of the
immunoblot normalised to tubulin immunoreactivity con-
firmed that there was no significant difference in the 100 kDa
intensity band between AD and control brains. However, the
immunoreactive intensity of 50 kDa, 37 kDa, and 50 + 37 kDa
was all significantly elevated inADbrain compared to control
brain (𝑃 ≤ 0.05%.) (Figure 7(b)), indicating the possibility
that 𝐶-terminal truncated DPP10
789
may be aggregating and
thus may be directly involved in the formation of neurofibril-
lary tangles and dystrophic neurites in AD brain.
4. Discussion
DPP10
789
is a dipeptidyl peptidase-like protein that together
with Kv-channel interacting proteins (KChIPs) forms mul-
tiprotein complexes that underlie subthreshold A-type cur-
rents (𝐼
𝑆𝐴
) in neuronal somatodendritic compartments [28].
This is the first study to assess the expression of DPP10
789
in postmortem brain samples in AD and other major tauo-
pathies. Using immunohistochemistry we reveal predomi-
nant neuronal staining ofDPP10
789
throughout the neocortex
and subcortical greymatterswith high expression in the pyra-
midal cells in control brain tissue. In contrast, in AD brains,
robust DPP10
789
reactivity was also detected in neurofib-
rillary tangles and plaque-associated dystrophic neurites,
most of which colocalized with the hyperphosphorylated
Ser-202/Thr-205 tau epitope. DPP10
789
positive neurofibril-
lary tangles and plaque-associated dystrophic neurites also
appeared in other neurodegenerative diseases such as FTLD,
DBLB, and PSP. Occasional DPP10
789
positive neurofibrillary
tangles and neurites were seen in some aged control brains.
Furthermore using a quantitative analysis we showed that
truncated DPP10
789
fragments increased significantly in AD
brains compared to control brains. These results provide the
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Figure 6: The regional distribution of DPP10
789
positive NFTs and NPs compared with phosphotau positive NFTs and amyloid-𝛽 positive
plaques. The adjacent free-floating sections of hippocampus or cortex were immunostained with DPP10
789
, AT8, or A4 antibody separately
using the DAB reaction. (a) The distribution patterns of DPP10
789
positive NFTs and tau positive NFTs in AD hippocampal sector. Three
fields (0.01mm2/field) per case from each region of Ammon’s horn (CA1-4) were counted. (b) In the cortex sector of AD brain, the number
of DPP10
789
positive NFTs and NPs was compared with tau positive NFTs and amyloid-𝛽 positive NPs. Three fields (0.01mm2/field) per case
were counted in each of layers III to V. Bars reflect mean ± SE (𝑛 = 9; observations from 3 fields/case × 3 cases).
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Figure 7: Truncated 𝑁-terminal DPP10
789
levels were elevated
in AD hippocampus relative to control hippocampus. 50 𝜇g of
solubilised fractions prepared from fresh-frozen AD and control
hippocampus was subjected to immunoblot analysis with DPP10
789
antibody and class III 𝛽-tubulin antibody (a). Quantification of
immunoblot data (b). The value of 𝑦-axis represents the relative
immunoreactivity normalised to tubulin expression level. Bars
representedmean ± SE of duplicate determination from five AD and
four control hippocampal homogenates. “∗” represented one-tailed
𝑡-test 𝑃 ≤ 0.05%.
first evidence that DPP10
789
may be involved in the pathology
of AD and other neurodegenerative diseases.
Our immunohistochemistry studies revealed that in con-
trol brains DPP10
789
immunoreactivity is located in the cell
body of neurons throughout the greymatter of cerebral cortex
and axonal fibre tracts of white matter (Figures 2(a) and
3(a)), suggesting that DPP10
789
protein is widely distributed
in the neuronal cells which is consistent with the expression
of DPP10 mRNA reported in rat brain [28]. In human
there are potentially four DPP10 mRNA isoforms which
all have unique amino acid sequences in the 𝑁-terminal
intracellular domain but identical 𝐶-terminal extracellular
domains [31]. Multiple DPP10 isoforms have been observed
by both Northern blot and reverse transcriptase PCR in
both human brain and pancreas; however it is not known
which transcript on the Northern blot represents DPP10
789
or whether any of these mRNA isoforms are translated into
different forms ofDPP10 protein in vivo [27, 31–33]. Takimoto
et al. demonstrated the presence of four DPP10 mRNA
isoforms in human brain. These isoforms are different only
at the 𝑁-terminal amino acid sequence. When the different
𝑁-terminal forms ofDPP10were co-expressedwith theKv4.3
channel there were no differences in the gating ability of the
channel [31]. In their study DPPYd is equivalent to DPP10
789
and this form was also detected in rat brain. Interestingly
Takimoto et al. were unable to detect DPP10
796
in the adrenal
gland and pancreas of humans or rats. In our laboratory we
have found it extremely difficult to use reverse transcriptase
PCR to amplify the other DPP10 isoforms (data not shown)
from either postmortem brain tissue or neuronal cell lines;
therefore these mRNA transcripts and thus protein isoforms
appear to be present in very low amounts in human tissues.
Throughout the cortex of AD cases, although the back-
ground distribution pattern of DPP10
789
is similar to con-
trols, it was the neurofibrillary tangles and plaque-associated
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dystrophic neurites that, by virtue of their intense DPP10
789
staining, stand out compared to controls (some aged controls
also had a few DPP10
789
tangles). Our data also revealed
that the DPP10
789
positive tangles and plaque-associated
dystrophic neurites are distributed mainly in layers III–V
pyramidal cells of the neocortex and CA1 and CA2 pyramidal
cells of the hippocampus in AD brains, consistent with
the distribution of Kv4.2 and Kv4.3 subunits in brain [34].
DPP10 interacts with both Kv4.2 and Kv4.3 subunits [17,
35]. Additionally, Kv4 channels play important roles particu-
larly in regulating neuronal membrane excitability; therefore
these results indicate that deposition of DPP10
789
protein in
these neurons may contribute to loss of channel function
and lead to neuronal dysfunction and cell death in AD.
Double immunofluorescence staining revealed that most
of the DPP10
789
positive tangles were colocalized with the
hyperphosphorylated phospho-Ser-202/Thr-205 tau epitope.
In addition, the intrahippocampal distribution of DPP10
789
positive NFTs followed the pattern established for phospho-
Ser-202/Thr-205 tau positive NFTs; however the amount of
DPP10
789
positiveNFTswas always less than that of phospho-
Ser-202/Thr-205 tau (Figure 6(a)). This implies that, while
AT8 can detect all six isoforms of human tau protein in brain
[36], DPP10
789
may only be present in tangles containing a
subset of the six isoforms. On the other hand, in the entorhi-
nal cortex region, some DPP10
789
positive tangles were
devoid of either AT8 (Figure 5(h)) or Tau2 (data not shown)
antibody staining, indicating that DPP10
789
did not always
cooccur with tau in tangles and it may on its own be involved
with tangle formation without tau involvement. It is also
possible that our DPP10
789
antibody can detect the late stage
of tangles—the ghost tangles which have lost the phospho-
Ser-202/Thr-205 tau epitope recognised by the AT8 antibody
[37, 38]. Recently Lace et al. reported that the RD3 anti-
body that specifically recognises the 3-repeat tau shows an
increased immunoreactivity in late-state ghost tangles [39].
Do RD3 positive tangles colocalize with DPP10
789
positive
staining? Which tau isoform may be involved in DPP10
789
positive tangle formation? To answer these questions, further
study needs to be done by using different tau antibodies
specific to different tau isoforms.
Tau is a microtubule-associated protein and predomi-
nantly found in axons [40–42]. The best known functions of
tau are the stabilization of microtubules and the regulation
of axonal transport [43, 44]. Recently it was reported that
tau has also been localized to dendrites under physiological
conditions and at much lower levels [45]. In addition to its
interaction with tubulin, tau binds to other partners such as
the tyrosine protein kinase Fyn, dynactin, and postsynaptic
density protein 95 (PSD95) [45–47]. Both tau-Fyn and tau-
PSD95 interactions are involved in the complex formation of
NMDA receptors with PSD95, which is required for excito-
toxic downstream signalling, suggesting that the distribution
of tau in dendrites is pivotal to healthy neurons [45, 47].
Noticeably, the intracellular distributions of Kv4 channels
are also predominant in dendrites [34]. Besides, it has been
reported that PSD95 has physical interactions with Kv4.2
[48, 49], suggesting that PSD95 may be involved in forming
complexes between Kv4.2 and signalling molecules. Because
the dendritic A-type potassium current strongly influences
the induction of long-term potentiation also by NMDA
receptors [50, 51], it is possible that there exist some signalling
connections between tau, Fyn, PSD95, and Kv4. As a Kv4
channel associated protein, DPP10 also has the potential to
be involved in these connections. However, so far there is
no direct evidence showing that tau interacts with Kv4, and
one possible explanation is that these protein interactions
may be transient or unstable; thus it is difficult to detect the
interactions using immunoprecipitation, immunostaining
techniques, or other proteomic based methods.
DPP10
789
positive immunoreactivity was also observed in
dystrophic neurites in A𝛽 aggregated senile plaques. It was
found that DPP10
789
positive dystrophic neurites did not col-
ocalize but mingled with the A𝛽 deposition core of the senile
plaques. This is consistent with the fact that plaques are
composed of extracellular aggregated A𝛽, while DPP10
789
,
according to our studies, is distributed intracellularly or in
the membrane [26, 27]. In addition, we have observed that
the number of DPP10
789
positive neurofibrillary tangles and
plaque-associated dystrophic neurites present in AD is much
more than that observed in other tauopathies (Table 3). As
the accumulation of A𝛽 is a primary event driving AD patho-
genesis, our finding indicates that DPP10
789
may be involved
some way in the pathogenic process. So far, the mechanisms
by which A𝛽mediates neurotoxicity and initiates the degen-
erative processes of AD are still not clear. Recent studies
revealed that A𝛽 inhibits the dendritic A-type K+ current
in outside-out patches excised from distal dendrites of hip-
pocampal CA1 pyramidal neurons, causing increases in back-
propagating dendritic action-potential amplitude and asso-
ciated Ca2+ influx. These results suggest that the sustained
increased dendritic Ca2+ influx, which results fromA𝛽 depo-
sition in dendritic arborisation that induces persistent inhibi-
tion of the A-type K+ current, may cause a loss of Ca2+ home-
ostasis in dendrites of hippocampal neurons, an initiating
event of synaptic failure and neurodegeneration [52].Whether
DPP10
789
is involved in this procedure needs further study.
The quantitative immunoblot on human brain sam-
ples showed that naturally in vivo two truncated forms of
DPP10
789
are observed and the levels of these increase in
AD brains compared to control brains, which has led us to
hypothesise that the truncated forms may form aggregates
in NFTs and dystrophic neurites. As there was no change in
the full-length form of DPP10
789
between control and AD
patients, it is assumed that if there is any increase in protein
production in AD, the newly formed protein is likely to be
rapidly degraded. DPP10
789
is a glycosylated transmembrane
protein with a large extracellular 𝐶-terminal domain and
a short intracellular 𝑁-terminal domain. The presence of
DPP10
789
in NFTs and dystrophic neurites but not amyloid
protein aggregated plaques suggests thatDPP10
789
is confined
to the neuronal cytoplasm. These observations suggest the
possible aberrant trafficking of DPP10
789
in degenerating
neurons.
DPP10 belongs to DPP4 gene family, some members of
which have been reported to have multiple functions. Previ-
ous in vitro studies showed that DPP4 and FAP have roles in
the cell-extracellular matrix interactions and apoptosis, and
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these functions are independent of catalytic activity [53]. It
is likely that most protein-protein interactions would occur
on the 𝛽-propeller domains of these proteins [54]. With 47%
amino acid similarity toDPP4, it is possible that DPP10, apart
from associatingwith Kv4 channel complex through its single
transmembrane domain [55], may also interact with other
proteins and ligands via either its extracellular 𝛽-propeller
domain or its intracellular domain and these interactionsmay
control its biological function in normal and pathological
conditions. Recently Lin et al. elegantly demonstrated that
the highly related DPP6 interacts with filopodia-associated
myosin and fibronectin within the extracellular matrix to
play a role in hippocampal synaptic development [56]. In
addition, DPP6 has been shown to interact with prion protein
tomediate potassium channels and neuronal excitability [57].
In summary this paper reports the first evidence that
DPP10
789
protein is present in NFTs and dystrophic neu-
rites in AD. Interestingly, DPP10
789
protein colocalizes with
hyperphosphorylated tau protein but not with A𝛽. Moreover
in neurodegenerative cases other than AD where neuronal
tau pathology occurred, the same regions showed intense
staining for DPP10
789
. In addition this paper provides initial
evidence that, as with other proteins involved in neurodegen-
erative diseases, DPP10
789
𝐶-terminal truncation may lead
to mistrafficking and aggregation of DPP10
789
protein but at
this point it is unclear whether this occurrence contributes
to AD pathology or is a result of AD pathology. Together
this data suggests that DPP10 may play a significant role in
the neurodegenerative process observed in AD and further
investigation into this role and its interaction with tau is
warranted.
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